World Sleep Industry ENCYCLOPEDIA

Sleep Product Real-World Research

6.5.1

Definition, intended uses, and business boundaries

Sleep product real-world research uses data routinely generated during health care, home, community, institutional, or market use to evaluate how a specified sleep-related product is used and its safety, performance, acceptability, and potential benefits or risks under actual conditions. Real-world data may come from electronic health records, registries, claims and prescriptions, complaints and vigilance systems, sleep diaries, patient-reported outcomes, wearables, home monitors, or product logs. Such data become real-world evidence only after a defined question, fit-for-purpose governance, an appropriate design, and a valid analysis have turned them into clinical evidence. A real-world setting does not by itself make data complete, remove bias, or make a result adequate for a product claim.

The service may address post-market surveillance, use patterns, long-term performance, comparative effects, underrepresented populations, questions about labeling or instructions, and planning of subsequent trials. Products may include medicines, medical devices, digital health technologies, general wellness products, bedding, light, sound, or thermal systems, and other consumer products. Each has a different legal classification, intended use, and evidentiary threshold. Intervention must also be classified separately: a fully observational study, a randomized study embedded in routine practice, and a study in which investigators change a product or algorithm may be subject to different authorization, registration, and safety requirements. The phrase real world does not exempt an interventional study from its clinical research obligations.

This service is distinct from manufacturing, release testing, laboratory performance testing, conformity assessment, event operations, data hosting alone, privacy consultancy, and routine clinical care. A contract research organization may perform protocol, site, data, statistical, or reporting activities, but the sponsor retains applicable oversight and ultimate responsibilities. A research report, ethics approval, test report, standards-conformity statement, or consultant opinion is not regulatory approval and does not by itself make the studied product clinically proven effective.

Research question, design, and comparison methods

The project should begin with an answerable intended use: the target population, exact product and version, comparator, start of exposure, duration of observation, primary and safety outcomes, and whether the result is intended for science, risk management, procurement, or regulatory discussion. The protocol should prospectively define eligibility, index date, baseline and follow-up windows, primary and secondary analyses, subgroups, multiplicity, missing-data handling, and sensitivity analyses. If the work may support a product claim, the population, setting, dose or mode of use, configuration, outcome, and time horizon in that claim should each map to the design.

Possible designs include cohort, case-control, self-controlled or before-after studies, registry studies, pragmatic randomized trials, and externally controlled studies. The question should determine the design rather than the convenience of an available database. Observational comparisons must address confounding by indication, healthy-user effects, disease severity, concomitant care, channel differences, and changes over calendar time. Restriction, matching, stratification, weighting, regression, or target-trial emulation may help, but no model can recover an important variable that was never measured. Before-after changes may reflect natural fluctuation, regression to the mean, season, expectations, co-interventions, or device learning and cannot all be attributed to the product.

A comparator should address the same clinical question over a comparable time window and have a defensible basis for exchangeability. Historical or external controls require examination of differences in data capture, enrollment, outcome definitions, and clinical practice. Sleep products may change hardware, formulation, firmware, recommendation algorithms, or interfaces while in use. Version, effective date, and migration rules must therefore be recorded. Pooling materially different versions can yield an estimate that corresponds to no specific product available for purchase or regulatory review.

Data sources, product exposure, and sleep outcomes

Data sources should be selected for fitness for the specific purpose, considering population coverage, availability of essential variables, longitudinal continuity, accuracy, completeness, traceability, the process that generated the data, and access to a validation sample. Claims data can characterize health-care use but often lack detailed sleep phenotypes. Electronic health records contain clinical detail but reflect care-seeking and local documentation practices. Complaints, returns, and vigilance records can reveal problem signals but rarely provide an unbiased incidence denominator. Wearables and applications can capture frequent home measurements, while algorithms, wear behavior, synchronization, and missingness can change the result. Linkage across sources should validate person matching, time alignment, duplicates, and linkage error.

Exposure is more than purchase or account activation. Research should identify model, lot, or software version; actual start, frequency, duration, dose or setting; adherence; interruption; shared use; replacement; and concurrent products. Medicines, devices, digital functions, and general consumer goods also require distinct treatment of prescription versus actual use, consumable replacement, remote parameter changes, algorithm updates, and uncertainty about the identity of the user. Exposure misclassification can dilute or manufacture an association, and data after a version change are not automatically equivalent to earlier data.

Sleep outcomes should be separated by measurement level. Diaries and validated scales can describe perceived sleep onset, awakenings, sleep quality, and daytime function. Actigraphy can estimate rest-activity patterns. Polysomnography can measure sleep stages, arousals, respiratory events, and movements. Health-care use, accidents, discontinuation, returns, and adverse events answer different questions. A consumer deep-sleep value or sleep score is not automatically equivalent to electroencephalographic staging or a clinical diagnosis. Device and algorithm version, valid-night rules, time zone, manual edits, and derivation formulas must be fixed. Workdays, free days, season, shift work, caffeine, alcohol, medication, comorbidity, bedding, light, sound, temperature, and bed partners may all affect sleep and should be measured or discussed according to the protocol.

Commissioning, conduct, and deliverables

Before commissioning, the parties should create a research-question brief, a product and claims inventory, the intended use, a feasibility assessment, and due diligence on each data source. The contract should distinguish the sponsor, research organization, care site, data holder, technology provider, statistician, and subcontractor. It should allocate scientific decisions, participant protection, escalation of safety signals, controller or processor responsibilities, intellectual property, publication independence, conflicts of interest, and authority for regulatory communication. Outsourcing work does not transfer the sponsor's duty of oversight. Critical subcontracting, offshore processing, and methodological changes should remain visible and controlled.

A typical workflow includes the protocol and statistical analysis plan; ethics and, where applicable, regulatory determinations; registration or public posting of the plan; data dictionary and common data model; extraction and transformation; quality checks; analysis-set lock; primary and sensitivity analyses; medical and safety review; reporting; and archiving. Prospective collection or embedded intervention may additionally require recruitment, informed consent, study supplies, site training, deviation management, and adverse-event reporting. Material changes to protocol, endpoints, or code should be approved and recorded before results are examined. If new information requires a change, its time, reason, impact, and need for supplemental analysis should be disclosed.

An acceptable delivery is more than a slide presentation. It ordinarily includes the final protocol, statistical analysis plan, description and fitness assessment of data sources, variable and code lists, product-version mapping, cleaning and derivation rules, quality report, analytic code and computational environment, tables and figures, deviation and decision logs, safety issue list, study report, limitations, and a reproducible archive. If privacy or licensing prevents delivery of row-level data, the contract should still allow the customer and legally authorized reviewers to examine provenance, transformations, code, aggregates, and audit trails.

Quality control, bias, and statistical interpretation

Quality should be designed into the study rather than repaired at the end. The project should identify factors critical to participant protection and reliable conclusions, such as exposure identification, primary outcomes, key confounders, follow-up completeness, product version, serious adverse events, and analytic reproducibility. Source verification, programmed checks, medical coding review, dual review, or independent validation can then be scaled to risk. Data quality is use-specific: a database suitable for disease surveillance may still be unable to distinguish sleep product versions or measure sleep-onset latency accurately.

An executable protocol, code lists, and analysis plan should be frozen before analysis. Original extracts, transformation logs, data versions, code versions, run records, and result checks should be retained. Analyses should assess selection bias, information bias, misclassification, confounding, time-related bias, loss to follow-up, and competing risks. Reports should show cohort construction, exclusions at each stage, baseline balance, observable time, validation of event definitions, missingness, model assumptions, effect estimates, and uncertainty intervals. Negative controls, quantitative bias analysis, alternative definitions, lag periods, adherence thresholds, and sensitivity to unmeasured confounding can test robustness, but the most favorable of many analyses must not be relabeled as the prespecified primary result.

Association is not necessarily causation, statistical significance is not clinical importance, and a group average does not guarantee an individual benefit. A very large dataset can make a trivial difference significant but cannot remove systematic bias. Safety studies should distinguish signal detection from causal confirmation. Comparative effectiveness work should state the estimand, absolute and relative effects, baseline risk, follow-up duration, and population to which the estimate applies. Failed, negative, and inconclusive findings require the same faithful retention and reporting as favorable findings.

Data security, ethics, and compliance

Real-world research may still be health research involving people. Scientific and ethics review, an informed-consent or waiver determination, applicable registration, and regulatory communication should be based on the degree of intervention, identifiability, product category, and local rules. A waiver does not remove ethical duties; the record should explain why renewed consent is impracticable or inappropriate, whether risk is minimal, and how rights are protected. Direct-to-consumer recruitment, in-app consent, and long privacy notices should not use a default box as a substitute for understanding and voluntariness. Withdrawal from research should not improperly reduce essential service or clinical care.

Data governance should apply purpose limitation, data minimization, layered authorization, strong authentication, protected transfer and storage, logs, backup and recovery, vulnerability response, retention periods, and secure deletion. Removing names does not necessarily anonymize data: sleep time series, location, device identifiers, audio, video, and rare-condition combinations may permit reidentification. Linked data, cloud services, cross-border transfers, secondary use, and vendor reuse need a lawful basis, clear notice, contractual restrictions, and risk assessment. Research data must not quietly become training data or commercial profiling beyond the communicated purpose.

Projects need triage rules for adverse events, product complaints, data breaches, incidental clinical findings, and urgent hazards. A dashboard alert cannot replace diagnosis by a qualified clinician, and an unvalidated consumer-device anomaly should not automatically create a diagnosis. Medicines, devices, foods, general wellness products, and consumer goods are subject to different vigilance, advertising, research, and recordkeeping rules. Multijurisdictional projects should assess each location rather than treating registration, ethics approval, or a conformity document from one jurisdiction as global authorization.

Evidence reporting, procurement, and claim boundaries

Reporting should let a reviewer reconstruct the question, sources, product version, cohort formation, exposure and outcome definitions, confounding control, statistical methods, deviations, missingness, safety findings, conflicts, and limitations. Observational studies can follow the applicable reporting guideline, while interventional trials must follow relevant registration and results-disclosure requirements. Favorable, negative, and inconclusive findings should all be reported, with prespecified and exploratory analyses clearly separated. A report may describe an association, use performance, or a comparison under specified conditions, but its conclusion must remain within the studied population, product configuration, setting, and time period.

Procurement should examine competence in epidemiology, sleep medicine, statistics, data engineering, security, and regulation; the verifiability of prior work; standard procedures; conflict management; subcontractor transparency; data access and exit arrangements; and the ability to deliver reproducible code and audit records. Pricing should separate data licensing, linkage, medical coding, statistics, technology validation, ethics, and safety work, rather than allowing a large sample size to conceal missing essential variables. Acceptance criteria can include timely protocol lock, validation of critical variables, closure of queries, reproduction of analyses, closure of deviations, and complete archiving. Payment should never depend on obtaining a significant or favorable result.

Real-world research can complement randomized trials and laboratory evaluation by showing routine use, longer-term performance, and experience in broader populations, but it does not automatically replace evidence proportionate to a particular decision. One vendor analysis, an internal dashboard, user testimonials, a before-after chart, or an unvalidated sleep score cannot establish efficacy, safety, causality, or official recognition. Phrases such as real-world validated, clinical grade, significantly improves, or zero risk must match the product itself, intended use, study design, complete evidence, and local requirements. A change in product, algorithm, formulation, use condition, or claim requires reassessment of whether prior evidence still applies.